August 6, 2025Open Access

Nomogram Model Based on Serum Metabolic Biomarkers to Predict Outcomes of First-Line Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Better outcomes linked to non-diabetic status and specific serum metabolic biomarkers in patients with advanced NSCLC.
The nomogram's concordance index for progression-free survival was 0.759 and 0.729 for overall survival, indicating strong predictive ability.
This analysis utilized a retrospective approach with 112 patients receiving first-line chemoimmunotherapy over three years.
Nomograms based on serum biomarkers could enhance personalized treatment strategies in clinical practice.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis shows serum metabolic biomarkers predict survival in advanced non-small cell lung cancer, suggesting personalized treatment guides.

Cite This Study

Zeng et al. (2025) studied this question.

synapsesocial.com/papers/68af2974cf1dd9ea359e2dcf https://doi.org/10.20944/preprints202508.0228.v1

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows serum metabolic biomarkers predict survival in advanced non-small cell lung cancer, suggesting personalized treatment guides.

Nomogram Model Based on Serum Metabolic Biomarkers to Predict Outcomes of First-Line Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer

Key Points

Discussion

Implication

Cite This Study

Nomogram Model Based on Serum Metabolic Biomarkers to Predict Outcomes of First-Line Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading